Cite
HARVARD Citation
Billingsley, C. et al. (n.d.). Evaluation of the Hematologic Safety of Same Day Versus Standard Administration (24- to 72-Hour Delay) of Pegfilgrastim in Gynecology Oncology Patients Undergoing Cytotoxic Chemotherapy. International journal of gynecological cancer. 25 (7), pp. 1331-1336. [Online].